Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
3Customers
3Debt Items
4Related Chains
Source-Backed Evidence Depth
PharmaCyte Biotech, Inc. (PMCB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
9Total relationships
3Distinct source URLs
5High confidence
0.800Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
PharmaCyte Biotech, Inc. Suppliers
Ticker
Name
Confidence
Evidence
AUSTRIANOVA
AUSTRIANOVA
92%
Austrianova is responsible for acquiring all of the necessary raw materials used in this process, including the cellulose sulfate necessary for encapsulating the live cells, a process proprietary to …
Reciprocal relationship from QCLS graph: ension or failure. This would not be considered to be within the Company’s control. The estimated fair value of the Series F-1 Preferred Stock on the issuance…
Reciprocal relationship from CNBX graph: Reciprocal relationship from PMCB graph: Reciprocal relationship from CNBX graph: Reciprocal relationship from PMCB graph: Reciprocal relationship from CNBX g…
ASSOCIATED-TECHNOLOGIES
ASSOCIATED-TECHNOLOGIES
62%
s of future revenue. Any sales or operating results will likely generally depend on volume and timing of orders, which may not occur and on our ability to fulfill such orders, which we may not be abl…
SMALLER-REPORTING-COMPANY
SMALLER-REPORTING-COMPANY
62%
pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for whic…
PharmaCyte Biotech, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
PMCB-DEBT
Debt stack $2.5M
90%
Market cache reports total debt of $2.5M.
PMCB-DEBT-11820
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-04-30.
PMCB-DEBT-11819
Warrants outstanding: 33993104
90%
xbrl warrant detail from xbrl 2025-07-31.
PharmaCyte Biotech, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for PharmaCyte Biotech, Inc..
PharmaCyte Biotech, Inc. Ownership
Holder
Name
Confidence
Evidence
PMCB-OWNER-CITADEL-ADVISORS-LLC
CITADEL ADVISORS LLC
90%
13F overlay lists CITADEL ADVISORS LLC as top holder; 32 tracked holders.
PharmaCyte Biotech, Inc. Extended Supply Chain Network
